| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BOLT Stock Overview
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system.
Bolt Biotherapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.27 |
| 52 Week High | US$19.29 |
| 52 Week Low | US$1.39 |
| Beta | 0 |
| 1 Month Change | -10.28% |
| 3 Month Change | 46.45% |
| 1 Year Change | -82.39% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -92.94% |
Recent News & Updates
Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M
Bolt Biotherapeutics press release (NASDAQ:BOLT): Q2 GAAP EPS of -$0.61 beats by $0.08. Revenue of $1.39M beats by $0.89M.
We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Shareholder Returns
| BOLT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.8% | 1.2% | 3.2% |
| 1Y | -82.4% | -21.7% | -10.2% |
Return vs Industry: BOLT underperformed the US Biotechs industry which returned -21.7% over the past year.
Return vs Market: BOLT underperformed the US Market which returned -10.2% over the past year.
Price Volatility
| BOLT volatility | |
|---|---|
| BOLT Average Weekly Movement | 14.0% |
| Biotechs Industry Average Movement | 12.6% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: BOLT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: BOLT's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 91 | Randy Schatzman | https://www.boltbio.com |
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade.
Bolt Biotherapeutics Fundamentals Summary
| BOLT fundamental statistics | |
|---|---|
| Market Cap | US$85.45m |
| Earnings (TTM) | -US$96.89m |
| Revenue (TTM) | US$3.47m |
24.7x
P/S Ratio-0.9x
P/E RatioIs BOLT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOLT income statement (TTM) | |
|---|---|
| Revenue | US$3.47m |
| Cost of Revenue | US$79.13m |
| Gross Profit | -US$75.66m |
| Other Expenses | US$21.23m |
| Earnings | -US$96.89m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.57 |
| Gross Margin | -2,182.92% |
| Net Profit Margin | -2,795.56% |
| Debt/Equity Ratio | 0% |
How did BOLT perform over the long term?
See historical performance and comparisonValuation
Is BOLT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BOLT?
Other financial metrics that can be useful for relative valuation.
| What is BOLT's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$85.45m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BOLT's PS Ratio compare to its peers?
| BOLT PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.9x | ||
XGN Exagen | 1.9x | 23.9% | US$84.4m |
GTH Genetron Holdings | 1x | 24.8% | US$84.3m |
TCRX TScan Therapeutics | 6.8x | -2.2% | US$84.3m |
AZYO Aziyo Biologics | 1.9x | 13.6% | US$87.5m |
BOLT Bolt Biotherapeutics | 24.7x | 66.9% | US$85.4m |
Price-To-Sales vs Peers: BOLT is expensive based on its Price-To-Sales Ratio (24.7x) compared to the peer average (2.9x).
Price to Earnings Ratio vs Industry
How does BOLT's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: BOLT is expensive based on its Price-To-Sales Ratio (24.7x) compared to the US Biotechs industry average (17.2x)
Price to Sales Ratio vs Fair Ratio
What is BOLT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 24.7x |
| Fair PS Ratio | 0x |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate BOLT's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of BOLT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BOLT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BOLT's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
Future Growth
How is Bolt Biotherapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
5.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BOLT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BOLT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BOLT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BOLT's revenue (66.9% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: BOLT's revenue (66.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BOLT is forecast to be unprofitable in 3 years.
Discover growth companies
Past Performance
How has Bolt Biotherapeutics performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-47.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BOLT is currently unprofitable.
Growing Profit Margin: BOLT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BOLT is unprofitable, and losses have increased over the past 5 years at a rate of 47.7% per year.
Accelerating Growth: Unable to compare BOLT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BOLT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).
Return on Equity
High ROE: BOLT has a negative Return on Equity (-46.59%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Bolt Biotherapeutics's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BOLT's short term assets ($181.3M) exceed its short term liabilities ($18.6M).
Long Term Liabilities: BOLT's short term assets ($181.3M) exceed its long term liabilities ($33.6M).
Debt to Equity History and Analysis
Debt Level: BOLT is debt free.
Reducing Debt: BOLT had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BOLT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BOLT has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 39.1% each year.
Discover healthy companies
Dividend
What is Bolt Biotherapeutics's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BOLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BOLT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BOLT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BOLT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BOLT has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
0.9yrs
Average management tenure
CEO
Randy Schatzman (67 yo)
3.08yrs
Tenure
US$5,935,603
Compensation
Dr. Randall C. Schatzman, also known as Randy, Ph D., has been the Chief Executive Officer and Director at Bolt Biotherapeutics, Inc. since July 2019. Dr. Schatzman co-founded Alder Biopharmaceuticals Inc....
CEO Compensation Analysis
Compensation vs Market: Randy's total compensation ($USD5.94M) is above average for companies of similar size in the US market ($USD759.99K).
Compensation vs Earnings: Randy's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: BOLT's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
Board Members
Experienced Board: BOLT's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Bolt Biotherapeutics, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Bolt Biotherapeutics, Inc.
- Ticker: BOLT
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$85.446m
- Shares outstanding: 37.64m
- Website: https://www.boltbio.com
Number of Employees
Location
- Bolt Biotherapeutics, Inc.
- 900 Chesapeake Drive
- Redwood City
- California
- 94063
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/14 00:00 |
| End of Day Share Price | 2022/08/12 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.